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DOI 10.1016/j.ccr.2011.11.006SUMMARYWe report that diffuse large B cell lymphoma (DLBCL) commonly fails to express cell-surface molecules
necessary for the recognition of tumor cells by immune-effector cells. In 29% of cases, mutations and dele-
tions inactivate the b2-Microglobulin gene, thus preventing the cell-surface expression of the HLA class-I
(HLA-I) complex that is necessary for recognition by CD8+ cytotoxic T cells. In 21% of cases, analogous
lesions involve the CD58 gene, which encodes a molecule involved in T and natural killer cell-mediated
responses. In addition to gene inactivation, alternative mechanisms lead to aberrant expression of HLA-I
and CD58 in >60% of DLBCL. These two events are significantly associated in this disease, suggesting that
they are coselected during lymphomagenesis for their combined role in escape from immune-surveillance.INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is themost common form
of adult non-Hodgkin lymphoma (NHL), accounting for 30%–40%
of cases (AbramsonandShipp, 2005). Based ongene expression
profile studies, threemain subtypes have been identified, namely
activated B cell-like (ABC), germinal center B cell-like (GCB), and
primarymediastinal B cell lymphoma (PMBCL) (Staudt andDave,
2005). These three subgroups appear to derive from distinct
cells of origin, are associated with common as well as distinct
genetic lesions, and,most notably, differ in their clinical response
to conventional therapeutic regimens (Lenz and Staudt, 2010).
Despite the significant progress in the identification of several
key genetic lesions and associated deregulated pathwaysSignificance
DLBCL is the most common type of lymphoma and includes se
ical features. We report that the majority of cases, including th
twomolecules are involved in the immune recognition of tumor
and NK cells. The frequency of these defects, the heterogenei
vation, and the significant co-occurrence of defects leading to
a strong selective pressure during lymphomagenesis. Overall,
as an important component of DLBCL pathogenesis.
728 Cancer Cell 20, 728–740, December 13, 2011 ª2011 Elsevier Inc(Klein and Dalla-Favera, 2008; Lenz and Staudt, 2010), a sizable
fraction of DLBCL remains incurable, suggesting that further
understanding in the pathogenesis of this disease is needed in
order to develop more specific therapeutic approaches.
The recent availability of technologies such as next-generation
sequencing and SNP array analysis is leading to the identifica-
tion of a large number of genetic alterations of possible patho-
genic significance in DLBCL (Morin et al., 2011; Pasqualucci
et al., 2011b). These studies have confirmed that GCB-type
DLBCLs are preferentially associated with t(14;18) transloca-
tions deregulating BCL2 (Huang et al., 2002), mutations within
the BCL6 autoregulatory domain (Iqbal et al., 2007; Pasqualucci
et al., 2003), and mutations of the chromatin modifier gene
EZH2 (Morin et al., 2010). Conversely, alterations preferentiallyveral subtypes with distinct genotypic, phenotypic and clin-
e two major subtypes, fail to express B2M and CD58. These
cells by two important arms of cellular immunity, namely CTL
ty of the involved mechanisms, including direct gene inacti-
the immune-escape from both CTL and NK cells, all suggest
these findings implicate the evasion of immune-recognition
.
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B2M and CD58 Inactivation in DLBCLassociated with ABC-DLBCLs include mutations leading to the
constitutive activation of NF-kB (Compagno et al., 2009; Davis
et al., 2010; Lenz et al., 2008; Ngo et al., 2011), translocations
deregulatingBCL6 (Iqbal et al., 2007; Ye et al., 1993), or inactiva-
tion of BLIMP1 (Mandelbaum et al., 2010; Pasqualucci et al.,
2006). In addition, genome-wide sequence and copy-number
analyses have identified lesions common to all DLBCL subtypes,
including the frequent inactivation of the acetyltransferase
genes CREBBP and EP300 (Pasqualucci et al., 2011a) and
of the trimethyltransferase gene MLL2 (Morin et al., 2011;
Pasqualucci et al., 2011b). Among the many altered genes, we
found b2-Microglobulin (B2M) and CD58, which were selected
for further analysis given their potential role in the recognition
of tumor cells by immune-surveillance mechanisms.
B2M is an invariant subunit required for the assembly of the
major histocompatibility complex (MHC) class I, together with
the human leukocyte antigen (HLA) heavy chain. The HLA-I
complex is present on the plasma membrane of most nucleated
cells (Bjorkman et al., 1987) and is involved in the presentation of
antigenic peptides derived from the degradation of endogenous
self or nonself proteins (Peaper and Cresswell, 2008), including
viral- or tumor-associated antigens (Townsend et al., 1985;
Zinkernagel and Doherty, 1974). These peptides are then recog-
nized by the T cell receptors of CD8+ cytotoxic T lymphocytes
(CTL), leading to the destruction of the target cells that present
nonself peptides. Several cancers, including colorectal carci-
noma, melanoma, and cervical carcinoma, lack cell surface
HLA-I expression due to heterogeneous mechanisms, thus
allowing their escape from immune recognition by CTLs (Garrido
et al., 2010; Hicklin et al., 1998). In particular, B2M gene lesions
associated with defective HLA-I expression have been reported
in a small number of lymphomas originating from the testis or the
central nervous system (Jordanova et al., 2003).
CD58, amember of the immunoglobulin superfamily, is a highly
glycosylated cell adhesion molecule that is expressed in diverse
cell types as a transmembrane or glycosylphosphatidylinositol-
membrane-anchored form (Dustin et al., 1987; Springer et al.,
1987). It acts as a ligand for the CD2 receptor, which is present
on T cells and most natural killer (NK) cells, and is required for
their adhesion and activation (Bolhuis et al., 1986; Kanner
et al., 1992; Wang et al., 1999), as documented by the observa-
tion that CD58 monoclonal antibodies lead to the diminished
recognition and cytolysis of the target cells by both CTLs and
NK cells (Altomonte et al., 1993; Gwin et al., 1996; Sanchez-
Madrid et al., 1982). Although certain cancers have been
observed to downregulate CD58 (Billaud et al., 1990), the mech-
anisms underlying the lack of expression are largely unknown.
The present study reports the comprehensive characterization
of a large panel of DLBCLs for the presence of B2M and CD58
genetic lesions as well as for the expression of the correspond-
ing proteins. The observed alterations have consequences for
the recognition of DLBCL by immune effector cells.
RESULTS
The B2M Gene Is Targeted by Mutations and Deletions
in DLBCL
Following the initial finding of B2M mutations in a ‘‘discovery
panel’’ of six DLBCL cases (Pasqualucci et al., 2011b), weCanperformed mutation analysis of the B2M coding exons in 126
additional DLBCL samples, including 105 primary biopsies and
21 cell lines (total n, including discovery cases = 132). We
identified 25 sequence variants distributed in 14/111 (12.6%)
DLBCL biopsies and 3/21 (14.2%) cell lines (Figure 1A; Table
S1 available online). Among these variants, 12 correspond to
inactivating frameshift insertions/deletions (n = 9) or nonsense
mutations (n = 3), resulting in transcripts that encode truncated
B2M proteins. Of the remaining 13 missense variants, 38%
(n = 5) affect the initiator methionine and convert it to arginine,
lysine, or threonine (ATG / AGG/AAG/ACG), thus abrogating
protein expression, as previously documented in the Burkitt’s
lymphoma cell line DAUDI (Rosa et al., 1983) (Figure S1A). Five
additional missense mutations are expected to inactivate the
protein function based on the PolyPhen prediction algorithm
(Sunyaev et al., 2001), whereas the remaining three amino acid
changes were located in the same allele carrying a premature
stop codon, and may thus represent passenger events. The
analysis of paired normal DNA in a subset of cases and the
screening of several databases of population polymorphisms,
including over 1,000 normal individuals (see Experimental Proce-
dures), indicate that the observed mutations represent somatic
events, overall accounting for 12.8% (n = 17/132) of the DLBCL
samples analyzed.
B2M mutations are present in both the GCB (n = 10/65)
and ABC/nonclassified (NC) (n = 7/67) DLBCL subtype (Fig-
ure 1B), but were not found in other mature B-NHL analyzed
(n = 108 cases, including 37 follicular lymphomas, 16 Burkitt’s
lymphomas, 44 chronic lymphocytic leukemias, and 11 marginal
zone lymphomas). These results suggest a specific role in the
pathogenesis of DLBCL.
To investigate whether the B2M locus is also a target of
copy number losses, we analyzed the 21 DLBCL cell lines and
80 of the 111 DLBCL biopsies (for which adequate material
was available) by fluorescence in situ hybridization (FISH) and
high-density SNP array analysis, respectively. Using these
approaches, we observed recurrent deletions affecting the
B2M locus in 24.7% (n = 25/101) of the cases (Figure 1C for
representative examples; Figures S1B and S1C). Notably,
40% (n = 10/25) of the affected samples harbored homozygous
deletions (Figure 1C and Figure S1C), an event only rarely
observed in other cancers with B2M lesions (Garrido et al.,
2010). The majority of the biallelic losses (n = 9) are <200 kb
in size and identify a minimal region of deletion centered on
the B2M locus. In fact, the smallest deletion (sample 2126)
spans only 30 Kb and selectively targets the B2M gene (Fig-
ure 1C; Table S1). Fifteen additional samples showed heterozy-
gous B2M deletions, of which four likely represent subclonal
events.
The combined analysis of both sequencing and copy-number
data revealed that 12.9% of cases (n = 17/132) have lost both
B2M alleles due to homozygous deletions (n = 9), biallelic muta-
tions (n = 4), or hemizygous deletions with mutations affecting
the second allele (n = 4), whereas 13.6% of cases (n = 18/132)
harbor monoallelic deletions (n = 12) or mutations (n = 6) (Fig-
ure 1E; Table S2). In three additional cases carrying truncating
mutations, the status of the second allele could not be deter-
mined due to the lack of suitable material for SNP array or
FISH analysis. The distribution frequency of B2M aberrations iscer Cell 20, 728–740, December 13, 2011 ª2011 Elsevier Inc. 729
Figure 1. The B2M Gene Is Targeted by Genetic Alterations in DLBCL
(A) Schematic representing the distribution of missense, nonsense, and frameshift mutations affecting the B2M genomic region in DLBCL biopsies and cell lines
(see also Table S1).
(B) Percentage distribution of B2M mutated samples in major DLBCL subtypes.
(C) dChip copy number heat map illustrating focal deletions affecting the B2M locus (arrow) on chromosome 15 in representative DLBCL samples. The first
three columns represent normal (diploid) samples (see also Figure S1 and Table S1).
(D) Distribution of homozygous and heterozygous deletions in GCB- and ABC/NC-DLBCL subtypes.
(E) Overall frequency and allelic distribution of B2M alterations, including mutations and deletions, in DLBCL.
D, deletion; M, mutation; WT, wild-type; nd, not determined.
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B2M and CD58 Inactivation in DLBCLcomparable in GCB- and ABC/NC-DLBCLs, accounting for
32.3% and 25.3% of the cases, respectively (Figure S1D).
Thus, overall 29% (n = 38/132) of all DLBCLs harbor genetic
lesions affecting the B2M locus, suggesting a critical role for
this gene in the pathogenesis of the disease.
B2M Missense Mutations Affect Protein Stability
Although the majority of the B2M mutations identified were
represented by unambiguously inactivating events, four of the
biallelically-affected samples harbored a missense mutation in
one of the two alleles (in the absence of secondary frameshift
or nonsense mutations in cis) (Table S2). These four samples
lack B2M expression by immunohistochemical (IHC) analysis
(Figures 2A and 2B; Table S2), despite the presence of detect-
able B2MRNA expression (data not shown). These observations
prompted us to investigate whether B2M missense mutations
induce protein instability. Toward this end, we introduced lentivi-
ral vectors encoding WT or missense mutant B2M alleles into
WSU, a DLBCL cell line lacking B2M protein expression due to
biallelic B2M gene inactivation (Table S2). All B2M missense
variant alleles expressed significantly less protein relative to
the WT allele, despite the presence of comparable B2M mRNA
levels, as measured by qRT-PCR analysis (Figure 2C). Taken
together, the results of the IHC and transient transfection anal-
ysis indicate that missense mutations cause the production of
unstable B2M proteins.730 Cancer Cell 20, 728–740, December 13, 2011 ª2011 Elsevier IncSeventy-Five Percent of DLBCL Display Aberrant B2M
Protein Expression
To examine the functional consequences ofB2M structural alter-
ations, we analyzed B2M protein expression in normal lymphoid
tissues, as well as in 53 DLBCL biopsies and 21 cell lines by IHC
analysis. In normal B cells, including germinal-center (GC) B
cells, B2M is predominantly expressed on the cell surface as
part of the MHC class I complex (Figure S2). However, 75% of
DLBCL samples either lacked B2M expression (n = 29/53) or dis-
played a variety of aberrant expression patterns, including
cytosolic (n = 8/53) or perinuclear Golgi (n = 3/53) localization
(Figures 3A and 3B). Although biopsies and cell lines with biallelic
B2M gene alterations exhibit negative staining, as expected,
a significant fraction of cases with monoallelic B2M inactivation
(n = 7/10) also displayed absent or mislocalized protein expres-
sion, suggesting silencing of the normal allele or the presence of
alternative mechanisms of B2M inactivation by improper subcel-
lular localization (Figures 3B–3D; Table S2). Furthermore, 11
cases with normal B2M alleles were also negative for membrane
B2M expression. Thus, the majority of DLBCL samples lack cell
surface B2M.
Defects in B2M Expression Are Associated with Loss
of Cell Surface HLA-I Expression
To investigate whether B2M genetic alterations result in per-
turbed cell surface HLA-I expression, we analyzed the same.
Figure 2. B2M Missense Mutations Affect Protein Stability
(A) Schematic representation of the B2M protein, with its N-terminal signal
peptide (SP) and C-terminal immunoglobulin (Ig)-like C1 domain. Missense
mutations are depicted by gray circles.
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Canpanel of DLBCL biopsies (n = 53) by IHC using the HC-10 anti-
body, which recognizes HLA-I (A, B, C) (Stam et al., 1990). We
observed positive, negative, or mislocalized HLA-I staining
patterns, directly mirroring the pattern of B2M (Figures 4A and
4B). In particular, all samples with normal cell surface B2M
expression show positive HLA-I staining (Figure 4C), whereas
cases with mislocalized B2M protein (n = 11) have either cyto-
solic or no HLA-I, indicating that the mechanisms responsible
for the perturbation of the normal B2M subcellular localization
can also affect the localization or stability of HLA-I proteins.
The remaining 29 samples, which lack detectable B2M expres-
sion, exhibited negative staining for HLA-I, with the exception
of two cases where the HLA-I protein was mislocalized. These
observations confirm that loss of cell surface B2M expression,
through genomic alterations or other yet uncharacterized
mechanisms, is associated with lack of membrane HLA-I in
DLBCL. Thus, overall, 75% (40/53) of DLBCL samples lack cell
membrane HLA-I expression.
Re-expression of Normal, but Not Mutant, B2M Proteins
Results in Restoration of Cell Surface HLA-I Expression
To confirm that the loss of HLA-I is indeed caused by absent or
mislocalized B2M expression, we designed experiments to rein-
troduce functional or missense B2M alleles in HLA-I negative
DLBCL cell lines. These experiments were also intended to
investigate whether lack of B2M expression had other effects
on the transformed phenotype of DLBCL cells, as suggested
by the proposed role of B2M in transducing the signal of the B
cell receptor (BCR), a major survival and proliferation signal for
B cells (Colonna et al., 1997; Takai, 2005). Flow cytometric anal-
ysis using the pan-HLA-I antibody W6/32 (Parham et al., 1979)
showed that, similar to DLBCL biopsies, the cell lines with
B2M biallelic alterations have significantly reduced (LY-1 and
SUDHL2) or absent (WSU) cell surface HLA-I expression (Fig-
ure 5A; Table S2). Transduction of these three cell lines with
lentiviral vectors expressing WT B2M alleles led to either
restoration (WSU) or a significant increase (LY-1 and SUDHL-2)
in cell surface HLA-I expression (Figure 5B). Conversely, trans-
duction of B2M missense mutants had no effects on HLA-I
expression, thus confirming the nonfunctional nature of these
mutants (Figure 5C). No other consequences on the transformed
phenotype, including proliferation and survival, were observed
(not shown). Taken together, these results demonstrate that
B2M inactivation is the underlying cause for the lack of HLA-I
plasma membrane localization in DLBCL.
Alterations Inactivating the CD58 Gene in DLBCL
The detection of recurrent copy number changes in CD58,
a gene known to be involved in the adhesion and activation of(B) Immunohistochemistry analysis of B2M in DLBCL biopsies (top panel) and
cell lines (bottom panel) harboring missense mutant alleles. The specific
alterations affecting each sample are indicated (D, deletion; M, mutation).
Scale bar represents 100 mm.
(C) Immunoblot analysis of B2M expression in WSU cells transduced with
bicistronic lentiviral vectors encoding WT or missense variants of B2M and
blasticidin downstream of an IRES element (actin, loading control). The bar
graph below shows the qRT-PCR quantification of the relative blasticidin
mRNA levels (mean +/ SEM), which reflect the abundance of B2M tran-
scripts, in the transduced cells.
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Figure 3. Frequent Loss of B2M Protein Expression in DLBCL
(A) Immunohistochemistry analysis of B2M expression in DLBCL biopsies. Shown are representative examples of the different subcellular localization patterns
including membrane (normal), perinuclear/Golgi (indicated by arrows), cytosolic, and no detectable staining (see also Table S2 and Figure S2). The genetic
configuration of the two B2M alleles is indicated for each case. Scale bar represents 100 mm.
(B) Top panel: overall percentage of DLBCL primary biopsies showing absent (negative), mislocalized, or normal (membrane positive) B2M expression. Bottom
panel: percent distribution of B2M expression, according to B2M genotype. Note that the ‘‘monoallelic’’ cases also include three samples where the status of
the second allele could not be determined. The total number of cases analyzed in each group is specified at the bottom.
(C) Immunoblot analysis for B2M and tubulin (loading control) in DLBCL cell lines carrying WT or genetically altered B2M alleles, as indicated.
(D) Immunohistochemistry analysis of B2M expression in representative DLBCL cell lines showing various subcellular distribution patterns. The status of the
B2M locus is indicated. Scale bar represents 100 mm.
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B2M and CD58 Inactivation in DLBCLmost NK cells as well as CTLs, prompted the targeted
sequencing of the CD58 coding exons in the same extended
panel of 132 DLBCL samples. This analysis revealed a total
of ten sequence variants, affecting 6.8% (n = 9/132) of the
samples (Figure 6A). Of these variants, 80% (n = 8/10) are
nonsense mutations, frameshift deletions/insertions or splice
site mutations that result in aberrant transcripts encoding for
truncated proteins, all of which lack the CD58 transmembrane
domain (Figure S3A; Table S3). The remaining two variants
were in-frame deletions, which result in the loss of either
Tyr119 or Ser98 in the extracellular domain of CD58, with pres-
ently unclear functional consequences (Figure 6A; Table S3).
CD58 mutations are distributed at comparable frequency in
both GCB- and ABC/NC-DLBCL (6.2% and 7.5%, respectively)
(Figure 6B).732 Cancer Cell 20, 728–740, December 13, 2011 ª2011 Elsevier IncHigh-density SNP array analysis revealed the presence of bial-
lelic or monoallelic deletions affecting the CD58 locus in 19.8%
of the samples analyzed (n = 17/80 biopsies and 3/21 cell lines)
(Figure 6C; Figure S3B; Table S3). Notably, the deleted regions in
two samples encompass only the CD58 locus, strongly indi-
cating that CD58 is the specific target of aberration in this region
(Figure S3B). Even though CD58 deletions were identified in
both DLBCL phenotypic subtypes, their frequency was signifi-
cantly higher in ABC/NC-DLBCL, where they account for 30%
(n = 15/50) of samples, as compared to 9.8% (n = 5/51) in
GCB-DLBCL (p < 0.01) (Figure 6D).
Based on the combined analysis of sequencing data and copy
number data, 21.2% (n = 28/132) of DLBCL samples harbor
either biallelic (n = 7/132, 5.3%) or monoallelic (n = 21/132,
15.9%) genetic lesions disrupting the CD58 gene (Figure 6E)..
Figure 4. Defects in B2M Expression Asso-
ciate with the Lack of Cell Surface HLA-I
(A) Immunohistochemistry analysis of HLA-I in
DLBCL samples using the HC-10 antibody, which
recognizes HLA-A, -B, and -C. The genetic status
of B2M is indicated for each sample. Scale bar
represents 100 mm.
(B) Percentage distribution of DLBCL samples
with negative, mislocalized, and positive HLA-I cell
surface expression.
(C) Relationship between B2M genetic status and
expression of the B2M and HLA-I proteins in
individual DLBCL biopsies. In the heatmap, each
column represents one DLBCL sample; the
genotype and staining patterns are color-coded as
indicated. *This category includes three mutated
samples where the status of the second allele
could not be determined.
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B2M and CD58 Inactivation in DLBCLThese alterations are more prevalent in ABC-DLBCLs (67.9% of
the lesions found) than in GCB-DLBCLs (32.1%) (Figure S3C).
Similar to B2M, PCR-amplified exon sequencing analysis of
other mature B-NHLs failed to detect any mutation, suggesting
that CD58 genetic lesions may be specifically selected during
DLBCL pathogenesis.
Frequent Loss of Cell Surface CD58 Expression
in DLBCL
Because DLBCL arises due to malignant transformation of
germinal center (GC) B cells, we first sought to determine the
expression pattern of CD58 in normal GC B cells. Gene expres-
sion profile analysis of purified tonsillar GC and naive B cells,
together with flow-cytometric analysis of reactive tonsils, con-
firmed that CD58 RNA and protein expression were high
in GC B cells relative to naive B cells (Figures S4A and S4B).
Accordingly, immunofluorescence analysis of human tonsillar
sections showed CD58 protein expression in GC B cells, but
not in naive B cells in the mantle zone (Figure S4C). In contrast
to normal GC B cells, IHC analysis of DLBCL biopsies showed
frequent negative or mislocalized protein expression (Figure 7A).
Among the cases with biallelic gene alterations, 75% (n = 3/4)Cancer Cell 20, 728–740, Dexhibited no protein expression (Fig-
ure 7B; Table S4); the remaining sample,
which harbors two disruptive mutations,
showed an abnormal cytosolic localiza-
tion pattern in the absence of membrane
staining, likely due to the expression
of truncated proteins that lack the
transmembrane domain, but which can
be nonetheless recognized by the poly-
clonal CD58 antibody. Interestingly,
87% of the monoallelically altered and
54% of the WT samples also showed
negative or mislocalized CD58 staining
patterns, strongly suggesting alterna-
tive pathogenic mechanisms for CD58
inactivation. As in the primary biopsies,
lack of surface CD58 protein expression
was observed in all of the DLBCL celllines harboring biallelic alterations (Figures S4D and S4E;
Table S4).
Overall, 67% of DLBCL biopsies and 19% of DLBCL cell lines
lack CD58 cell surface expression. Despite that genetic lesions
of CD58 were significantly more frequent in ABC/NC-DLBCL,
the percentage of cases showing absent or aberrant CD58
expression was similar in the two subtypes (GCB-DLBCL,
65%; ABC/NC-DLBCL, 68%) (Figure 7C; Figure S3C). Thus,
loss of CD58 surface protein expression is a frequent event
across all DLBCLs.
CD58 Contributes to NK Cell-Mediated Cytolysis
of DLBCL
To determine whether CD58 loss affects NK cell-mediated
lysis in DLBCL, we reintroduced the CD58 coding sequence
(long/transmembrane isoform), or control empty vectors, into
the HBL1 DLBCL cell line, which harbors a homozygous
deletion of the CD58 locus and hence lacks CD58 expression.
Reconstituted HBL1 cells were then tested as targets in NK-
mediated cytotoxicity assays. As shown in Figure 7D, re-expres-
sion of CD58 induced a significant increase in the percentage
of cytolysis (30%–50%, p < 0.001), when compared toecember 13, 2011 ª2011 Elsevier Inc. 733
Figure 5. Reintroduction ofWTB2M, but NotMutant Alleles Result in
Restoration of Cell Surface HLA-I
(A) Flow cytometric analysis of cell surface HLA-I expression in three
DLBCL cell lines harboring biallelic B2M lesions, and a B2M WT cell line. The
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734 Cancer Cell 20, 728–740, December 13, 2011 ª2011 Elsevier Incvector-transduced cells. Conversely, blocking cell surface CD58
with the anti-CD58 TS2/9 antibody (Le et al., 1990) in the RIVA
cell line, which expresses CD58, decreased the susceptibility
to NK lysis by 20%–26% (p < 0.001) (Figure 7E; Figures S4F
and S4G), whereas TS2/9 had no effect on the CD58-null
HBL1 cell line (Figure S4H). Together, these data demonstrate
that CD58 loss is involved in the recognition of DLBCL by NK
cells.
Most DLBCL Cases Lack Expression of both HLA Class I
and CD58 Proteins
Effective evasion of immune surveillance requires avoidance
of both CTL and NK cell recognition. Therefore, it is conceivable
that tumors would evolve to lose both HLA-I and CD58
and thus escape the recognition by both arms of cellular immu-
nity. Consistent with this notion, 61% of the DLBCL cases
analyzed concurrently lack HLA-I and CD58 on the cell surface
(Figures 8A and 8B) (p < 0.042), suggesting that these alterations
may be coselected during lymphomagenesis for their comple-
mentary roles in protecting fromCTL- andNKcell-mediated lysis.
DISCUSSION
B2M and CD58 Gene Inactivation in DLBCL
Our results indicate that direct inactivation of the B2M gene by
deletion and/or mutation occurs in a sizable fraction of DLBCLs.
B2M inactivation, whether biallelic or monoallelic, is often asso-
ciated with loss of protein expression. The type and distribution
of these lesions are analogous to those occasionally found
in melanoma (Hicklin et al., 1998) and cervical carcinoma
(Koopman et al., 2000). In addition, B2M genetic lesions have
been previously reported in a small number of DLBCL cases
originating from the testis or the central nervous system (n = 2
of 15 analyzed) (Jordanova et al., 2003) and in the Burkitt’s
lymphoma cell line Daudi (Rosa et al., 1983). Our results show
that B2M gene inactivation is a recurrent event in nodal DLBCLs
of both the GCB- and ABC-type, suggesting a pathogenetic role
in this disease (see below).
Inactivation of the CD58 gene by structural alterations had not
been previously appreciated in DLBCL and has not been
reported in other types of cancer. These lesions include trun-
cating mutations and focal deletions, often disrupting both
alleles, and affect 21% of DLBCL cases. As in the case of
B2M, CD58 lesions can be found in both major subtypes of
DLBCL, but not in other common lymphoidmalignancies derived
from mature B cells, suggesting that they represent pathoge-
netic mechanisms rather specific for this type of tumor.corrected mean fluorescence intensities (cMFI = HLA-I antibody MFI minus
isotype control MFI) are indicated. Note the complete lack of expression in
WSU, and the significantly reduced levels in two additional cell lines carrying
a B2M missense mutation with genetic loss of the second allele.
(B) HLA-I expression in the three DLBCL cell lines upon reintroduction of WT
B2M (blue), as compared to empty vector control (yellow). Western blot
analysis of B2M expression in the same cells confirms the presence of
exogenous B2M protein. Actin, loading control.
(C) Relative cell surface HLA-I levels (mean +/ SEM), assessed by flow
cytometry, in the WSU cell line reconstituted with vectors expressing WT or
missense mutants of B2M, as compared to empty vector (arbitrarily set as 1).
.
Figure 6. The CD58 Gene Is a Target of Genetic Alterations in DLBCL
(A) Schematic diagram of the CD58 gene (top) and protein (bottom), with its known functional domains (SP, signal peptide; Ig, Immunoglobulin single-pass type I
membrane; TM, transmembrane; C, cytoplasmic). Color-coded symbols depict distinct types of mutations (see also Table S3).
(B) Percentage of mutated samples in the GCB and ABC/NC-DLBCL subtypes.
(C) dChip SNP inferred copy number heatmap of the 1p13.1 region encompassingCD58 in representative DLBCL primary cases and three normal (diploid) DNAs
(see also Figure S3 and Table S3).
(D) Percentage of samples harboringCD58 deletions in GCB and ABC/NCDLBCL subtypes. The actual number of affected samples over total analyzed is shown
on top.
(E) Overall frequency of CD58 structural alterations in DLBCL (D, deletion; M, mutation; nd, not determined).
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B2M and CD58 Inactivation in DLBCLAdditional Mechanisms Lead to the Lack of Functional
B2M and CD58 Protein Expression in DLBCL
A notable finding of this study is that direct genetic lesions of
the B2M and CD58 genes represent only ‘‘the tip of the iceberg’’
of heterogeneous defects in the production of functional
B2M and CD58 polypeptides in DLBCL. In fact, additional
mechanisms lead to the complete lack of cell surface expression
of these molecules in over half of DLBCL cases. These mecha-
nisms include the lack of expression of the second allele in
cases with monoallelic gene inactivation, which is commonly
observed in tumor suppressor genes andmay be a consequence
of promoter hypermethylation or other epigenetic mechanisms.
More unexpected was the finding of mislocalized protein
expression in cases with either monoallelic gene inactivation
or WT alleles, observed for both B2M and CD58. The
basis for this functional alteration is unknown, and may
involve yet unidentified genetic lesions affecting proteins that
participate in the intracellular transport of B2M and CD58. B2M
mislocalization may also be due to defects in HLA-I expression
or assembly, which is required for cell surface localization
of B2M (Hughes et al., 1997). However, no recurrent copy
number alterations, mutations or abnormalities in RNA expres-
sion were detected in any of the candidate genes involved in
this process, including TAP1, TAP2, LMP2, and LMP7. Thus,
the identification of the mechanisms leading to mislocalizedCanB2M and CD58 expression will require further genomic and/or
functional screenings.
Loss of Functional B2M Leads to Lack of HLA-I
Expression and Escape from CTL
As expected, all cases lacking B2M cell surface expression were
also devoid of membrane HLA-I, independent of the mechanism
underlying the B2Mdefect (in total, 75%of all DLBCLs). Because
HLA-I is misfolded and subsequently degraded in the absence of
functional B2M (Hughes et al., 1997), the lack of HLA-I expres-
sion in these cases represents a consequence of B2M defects.
Consistent with this notion, restoration of B2M expression in
B2M null cell lines led to reexpression of HLA-I. In rare cases,
where the HLA-I protein is absent whereas the B2M protein is
mislocalized, the defects may reside in the HLA-I heavy chain
genes or in the transport machinery, because both are required
for proper B2M localization (Hughes et al., 1997; Peaper and
Cresswell, 2008). Indeed, deletions of various portions of the
HLA-I locus have been reported in DLBCL (Riemersma et al.,
2000), although direct evidence for the specific targeting of
HLA-I genes is missing. Overall, our results provide a genetic
basis and a mechanistic explanation to previous observations
on the lack of HLA-I expression in DLBCL.
The HLA-I complex presents antigenic peptides to CTL, which
then proceed to the destruction of the target cells. Thus, HLA-Icer Cell 20, 728–740, December 13, 2011 ª2011 Elsevier Inc. 735
Figure 7. Aberrant Expression of the CD58 Protein in DLBCL Affects NK Cell-Mediated Cytolysis
(A) CD58 protein expression in representative DLBCL biopsies (genomic status as indicated:D, deletion;M,mutated;WT,wild-type) (see also Table S4). Scale bar
represents 100 mm.
(B) Overall proportion of DLBCL biopsies showing defective CD58 surface expression (top). The relationship between CD58 genetic lesions and protein
expression pattern in individual cases is presented below. *This category includes five mutated samples where the status of the second allele could not be
determined.
(C) Frequency of cases showing aberrant CD58 surface expression in DLBCL subtypes.
(D) Percent NK cell-mediated cytolysis in HBL1 cells transducedwith lentiviral vectors expressing CD58 (or empty vectors) at various effector to target (E/T) ratios
(mean +/ SD; *p < 0.001). Data shown represents one of three independent experiments performed in triplicate (see also Figure S4).
(E) NK cell-mediated cytolysis in the DLBCL cell line RIVA (CD58WT) after blocking of cell surface CD58 by anti-CD58 TS2/9 antibodies (mean +/ SD; *p < 0.001;
**p < 0.01). Data shown represents one of two experiments performed in triplicate (see also Figure S4).
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and will remain invisible to T cell-mediated immune-surveillance.
The nature of the antigenic peptides that DLBCL cells fail to736 Cancer Cell 20, 728–740, December 13, 2011 ª2011 Elsevier Incpresent is unknown. Because these cases are not infected by
any known viruses, the involved antigens may be represented
by ‘‘tumor antigens’’ generated by the deregulated expression.
Figure 8. Concurrent Loss of Cell Surface
HLA-I and CD58 Is a Common Feature in
DLBCL
(A) B2M, HLA-I, and CD58 membrane protein
expression in individual DLBCL cases, color
coded as indicated. A two-tailed Fisher’s exact
test was used to determinewhether the correlation
in the expression patterns of HLA-I and CD58
was statistically significant (p < 0.042).
(B) Overall proportion of DLBCL biopsies showing
lack of HLA-I and/or CD58 surface protein
expression.
(C) Model for the mechanism of immune escape in
DLBCL. Lymphoma cells displaying tumor-asso-
ciated antigens through HLA-I can be recognized
and subsequently lysed by CTLs. To evade CTL
recognition, tumors often downregulate HLA-I
expression (top). However, HLA-I also acts as
a ligand for the NK cell inhibitory receptors that
transduce signals to counterbalance the activating
cues from receptors such as CD2. Thus, tumor
cells devoid of HLA-I are vulnerable to NK cell
attack via activation of the CD2 receptor by CD58
on the tumor cell (middle). In DLBCL, concurrent
loss of HLA-I and CD58 confers protection from
both T cell- and NK cell-mediated lysis (bottom).
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Bruggen, 1996).
Lack of CD58 Is Relevant for Recognition by Both CTL
and NK Cells
By acting as a ligand for the CD2 receptor on T and NK cells,
CD58 contributes to the adhesion and activation of both types
of immune effector cells. Accordingly, monoclonal antibodies
against CD58, which disrupt CD2/CD58 interactions, result in
diminished recognition and cytolysis of target cells by both CTLs
and NK cells (Altomonte et al., 1993; Gwin et al., 1996; Sanchez-
Madrid et al., 1982). The relevance of CD58 in tumorigenesis has
been previously suggested based on the observation that CD58
expression is downregulated in several cancer types, although
the underlying mechanisms are unknown. The results herein
confirm that variations in CD58 expression levels can influence
NK cell-mediated cytolysis of DLBCL cells in vitro (Figures 7D
and 7E), and suggest that loss of CD58 expression may contri-
bute to decreased recognition of DLBCL cells by NK cells in vivo.
Frequent Combined Loss of HLA-I and CD58 Suggests
Coselection during Lymphomagenesis
Although the lack of HLA-I expression in the majority of DLBCL
samples confers escape from CTL, the same event will stillCancer Cell 20, 728–740, Dtrigger recognition and lysis by NK cells
(Ka¨rre et al., 1986), an event unlikely to
be positively selected during lymphoma-
genesis. This paradox could be explained
by the observation that DLBCLs often
concomitantly lose the expression of
CD58, which may facilitate their escape
from both CTL and NK recognition
(summarized in Figure 8C). In support ofthis notion, 75.7% of the DLBCL cases lacking HLA-I expression
also lack CD58 expression. The significant association between
these two events suggests that they may be coselected during
lymphomagenesis for their combined role in the escape from
immune recognition.
Implications for DLBCL Pathogenesis and Therapy
The findings herein indicate that escape from recognition by
immune effector cells may represent a frequent pathogenetic
event in DLBCL, common to both the GCB and ABC subtypes.
This mechanism is likely to be an important contributor to the
development of DLBCL by complementing the defects in prolif-
eration, differentiation, and survival that are caused by other
genetic lesions present in these tumors. Alterations affecting
other molecules involved in immune recognition, such as the
T cell-recognition ligands PD-L1 and PD-L2 as well as the tran-
scriptional coactivator CIITA have been reported in PMBCL
and Hodgkin lymphoma (Green et al., 2010; Steidl et al., 2011).
Additionally, frequent loss of HLA-II in DLBCL has been sug-
gested to play an important role in CTL evasion (Rimsza et al.,
2004). These data further corroborate the hypothesis that
escape from immune-surveillance through multiple mechanisms
is a common feature of all DLBCL subtypes. Evasion from the
immune system may protect DLBCL cells from the recognitionecember 13, 2011 ª2011 Elsevier Inc. 737
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tumor suppressor genes (Boon and van der Bruggen, 1996).
The ability to escape from both the adaptive and innate immune
responses should be considered in the development of immuno-
therapeutic approaches for DLBCL.
EXPERIMENTAL PROCEDURES
Primary Samples
Primary biopsies from 111 newly diagnosed, previously untreated DLBCL
patients were obtained as paraffin-embedded and/or frozen material from
the archives of the Departments of Pathology at Columbia University andWeill
Cornell Medical College, after approval by the respective Institutional Review
Boards (Exempt Human Subject Research of anonymized/deidentified exist-
ing pathological specimens, under regulatory guideline 45 CFR 46.101(b)(4))
and their detailed characterization has been reported (Compagno et al.,
2009). Based on prior gene expression profile studies, the DLBCL cohort
(cell lines and primary biopsies) comprised 65 GCB-DLBCL and 67 ABC/NC
cases. Other B-NHL cases analyzed included 37 follicular lymphomas, 44
chronic lymphocytic leukemias, 16 Burkitt’s lymphomas, and 11 marginal
zone lymphomas.
Mutation Analysis
Targeted DNA sequencing of theB2M andCD58 coding exons was performed
by the Sanger method on PCR products obtained from whole genome ampli-
fied DNA (RepliG kit, QIAGEN). The somatic mutations identified through this
method were further confirmed by PCR amplification and double-strand
DNA sequencing of independent products obtained from high-molecular-
weight genomic DNA. The sequencing results were compared to the UCSC
Human Genome database reference mRNA sequence with accession number
NM_004048.2 forB2M andNM_001779 forCD58, using theMutation Surveyor
software as described (Pasqualucci et al., 2011b). In cases harboring more
than one mutation, their allelic distribution was analyzed by cloning and
sequencing of PCR products encompassing both sequence variants, obtained
from cDNA and/or high molecular weight genomic DNA. The PCR primers
used for genomic and cDNA amplification of B2M and CD58 are listed in the
Supplemental Experimental Procedures.
High-Density SNP Array Analysis
Genome-wide DNA profiles of 80 DLBCL primary cases and 11 paired normal
DNAs were obtained using the Affymetrix Genome-Wide Human SNP Array
6.0 (Affymetrix, Santa Clara, CA) as part of an independent study (Pasqualucci
et al., 2011b) and are available from the database of Genotypes and
Phenotypes repository (http://www.ncbi.nlm.nih.gov/gap) under accession
number phs000328.v1.p1. Copy number data for the DLBCL cell lines were
obtained from the Gene Expression Omnibus database (accession number
GSE22208). The detailed procedure for data processing and analysis is
described in Pasqualucci et al. (2011b).
Flow Cytometry
Analysis of cell surface HLA-I in DLBCL cell lines was performed using the
W6/32-FITC antibody (Abcam) (Parham et al., 1979). Cells were washed
twice for 5 min in PBS + 0.5% BSA and incubated for 30 min with 1 mg of
W6/32-FITC per million cells in 100 ml of PBS + 0.5%BSA on ice. The unbound
antibody was removed by washing the cells twice with PBS+0.5% BSA for
5 min followed by analysis on a FACSCalibur instrument (Becton Dickinson).
Data were analyzed using the CellQuest (Becton Dickinson) and FlowJo
softwares (TreeStar). Corrected mean fluorescence intensities (cMFIs) were
calculated by subtracting the MFI of cells labeled with an isotype control
antibody from the MFI of W6/32-FITC labeled cells. Cell surface CD58
expression was assessed using anti CD58-PE antibodies (AICD58, Beckman
Coulter) in the same protocol.
Immunohistochemistry
Paraffin embedded DLBCL tissue microarrays (TMAs) were constructed
as described (Compagno et al., 2009) and analyzed for B2M, HLA-I, and
CD58 protein expression by immunohistochemistry using standard protocols.738 Cancer Cell 20, 728–740, December 13, 2011 ª2011 Elsevier IncBriefly, antigen retrieval was performed in sodium citrate buffer (pH 6.0) in
a microwave. The sections were incubated with anti-B2M (1:2,000, DAKO),
HC-10 (1:100, a generous gift from Dr. J. Neefjes, Netherlands Cancer Insti-
tute, Amsterdam) (Stam et al., 1990), or anti-CD58 antibody (5 mg/mL, R&D
Systems, AF1689) overnight. For B2M and HLA-I, the sections were incubated
with secondary antibodies conjugated to horseradish peroxidase (HRP) (EnVi-
sion, Dako) followed by visualization with 3-amino-9-ethylcarbazole (Sigma).
For CD58, the sections were incubated with donkey anti-goat-biotin
secondary antibody (1:100, Jackson Immuno) followed by streptavidin-HRP
(1:100, Vector Lab), which was then visualized by 3,30-diaminobenzidine
substrate (Vector Lab). All sections containing >20% of tumor cells were
considered for scoring.Lentiviral Transductions
For the reconstitution studies, lentiviral vectors encoding B2M and CD58
were generated by replacing the GFP cassette of the pCCL.sin.PPT.hPGK.
GFPWpre vector (kindly provided by Dr. Luigi Naldini, Fondazione San
Raffaele, Italy) (Dull et al., 1998) with a B2M- or CD58-IRES-Blasticidin
cassette, respectively. Lentiviral vectors, along with helper plasmids encoding
D8.91 and the VSV-G envelope glycoprotein, were cotransfected into HEK293
cells, and the viral supernatant was used to infect DLBCL cell lines according
to standard protocols. In the B2M reconstitution experiments, transduced
cells were selected in Blasticidin (LY-1, 5 mg/mL; WSU, 1 mg/mL; SUDHL-2,
0.5 mg/mL) for 10 days before analysis. For the NK-mediated cytotoxicity
assays, HBL1 cells were used five days after transduction with CD58-express-
ing vectors, in the absence of selection.Immunoblotting
The expression of B2M and CD58 in DLBCL cell lines was analyzed by
standard immunoblotting protocols, using antibodies specific for anti-B2M
(Dako, 1:1,000) and anti-CD58 (AF1689, R&D Systems: 1:500; for the glycosy-
lated form, TS2/9, Biolegend: 1:200) (Le et al., 1990) specific antibodies. As
loading controls, the levels of b-actin (1:10,000, Clone AC-15; Sigma) or
b-tubulin (1:2,000, Clone B-5-1-2; Sigma) were measured.NK Cell Isolation and Cytotoxicity Assays
Peripheral blood mononuclear cells (PBMCs) were isolated from freshly
collected buffy coats (New York Blood Center) of healthy donors by Ficoll-
Hypaque (GE Healthcare) density gradient centrifugation. NK cells were
then isolated from PBMCs using the NK Cell Isolation Kit (130-092-657,
Miltenyi Biotec), and maintained in Iscove’s medium containing 5% FCS,
10% human AB serum (New York Blood Center), minimal essential amino
acids, sodium pyruvate, L-glutamine, and 2.5 U/ml of recombinant human
IL-2 (PeproTech) for 12 hr. For the cytotoxicity assays, target DLBCL cell
lines (HBL-1 and RIVA) either untransduced or transduced with lentiviral
vectors expressing CD58 were first labeled with 2.5 mM carboxyfluorescein
succinimidyl ester (CFSE, Invitrogen) for 24 hr. Target cells (T) (0.1 3 106)
were then incubated with effector NK cells (E) cells at a ratio (E/T) of 0:1,
1.25:1, 2.5:1, and 5:1 for 4 hr at 37C in 5% CO2, and the percentage of
cell death in the CFSE-labeled target cells was assessed by flow cytometric
analysis of 7-aminoactinomycin D (7-AAD) uptake. NK cell-mediated cyto-
toxicity was measured after subtraction of the background cell death
(E/T = 0:1). For the CD58-blocking experiments, RIVA or HBL1 cells were
incubated at 4C for 1 hr with either the anti-CD58 TS2/9 or an isotype
control antibody (both from Biolegend; final concentration, 10 mg/ml per
million cells). The blocking efficiency was assessed by staining the cells
with the anti-CD58 TS2/9-APC antibody (Biolegend) followed by flow cyto-
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